Sysmex (OTCMKTS:SSMXY) Shares Gap Up – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped up prior to trading on Friday . The stock had previously closed at $8.37, but opened at $8.8750. Sysmex shares last traded at $8.8750, with a volume of 530 shares trading hands.

Analyst Ratings Changes

Separately, Citigroup lowered shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Sysmex presently has a consensus rating of “Hold”.

Sysmex Stock Up 7.8%

The company has a market cap of $5.68 billion, a price-to-earnings ratio of 23.74 and a beta of 1.10. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The business has a fifty day moving average of $8.71 and a two-hundred day moving average of $9.10.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The business had revenue of $877.92 million for the quarter, compared to analysts’ expectations of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, equities analysts anticipate that Sysmex Corporation ADR will post 0.42 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.